Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov Web site. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 02/22/2011) - In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine.
Study of a Statin to Prevent Polyps after Colon Cancer Resection
(Posted: 02/08/2011) - In this trial, people who have undergone curative resection for stage I or II colon cancer will be randomly assigned to take either rosuvastatin (Crestor) or a placebo pill daily for 5 years to see if the drug can help prevent new colorectal tumors.
Dose-adjusted Chemotherapy for Untreated c-MYC-positive Lymphomas
(Posted: 01/25/2011) - In this trial, adult patients with newly diagnosed Burkitt lymphoma or c-MYC-positive diffuse large B-cell lymphoma will be separated into low-risk and high-risk groups; those in the low-risk group will be treated with at least three cycles of dose-adjusted EPOCH-R chemotherapy, while high-risk patients will receive six cycles.
Comparing First-line Therapies for Mucinous Ovarian or Fallopian Tube Cancer
(Posted: 01/11/2011) - In this trial, which is being conducted in both the United States and the United Kingdom, women with stage II to IV or recurrent stage I mucinous epithelial ovarian or fallopian tube cancer will be randomly assigned to receive either paclitaxel/carboplatin with or without bevacizumab or oxaliplatin/capecitabine with or without bevacizumab.
Targeting Tumor Metabolism in Papillary Kidney Cancers
(Posted: 12/14/2010) - In this trial, patients with hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cancer that has spread beyond the kidneys will be treated with erlotinib and bevacizumab.